Baker BROS. Advisors LP Buys Shares of 813,449 Dyne Therapeutics, Inc. $DYN

Baker BROS. Advisors LP bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 813,449 shares of the company’s stock, valued at approximately $15,911,000. Baker BROS. Advisors LP owned approximately 0.57% of Dyne Therapeutics at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Strs Ohio acquired a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd acquired a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $84,000. Steward Partners Investment Advisory LLC boosted its position in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after buying an additional 7,697 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in Dyne Therapeutics in the second quarter valued at approximately $111,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DYN. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research report on Friday, May 15th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, Chardan Capital reiterated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.85.

Dyne Therapeutics Price Performance

DYN stock opened at $19.20 on Thursday. The firm has a market cap of $3.17 billion, a price-to-earnings ratio of -5.96 and a beta of 1.09. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The company’s fifty day simple moving average is $18.27 and its 200 day simple moving average is $18.10.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the business posted ($1.05) earnings per share. On average, analysts expect that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 287,956 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total value of $5,666,974.08. Following the transaction, the director owned 11,663 shares in the company, valued at $229,527.84. The trade was a 96.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have acquired 9,000 shares of company stock valued at $156,800 and have sold 1,559,462 shares valued at $29,814,746. 9.46% of the stock is currently owned by insiders.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.